Pharmacosmos A/S
🇩🇰Denmark
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)
Phase 3
Completed
- Conditions
- Iron Deficiency AnaemiaIron Deficiency Anemia
- Interventions
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 1512
- Registration Number
- NCT02940886
- Locations
- 🇺🇸
Pharmacosmos Investigational Site, Tacoma, Washington, United States
🇺🇸Pharmacosmos Investigational Site 1, East Setauket, New York, United States
🇺🇸Pharmacosmos Investigational Site 2, East Setauket, New York, United States
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease
Phase 3
Completed
- Conditions
- Iron Deficiency AnemiaIron Deficiency AnaemiaChronic Kidney Disease
- Interventions
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 1538
- Registration Number
- NCT02940860
- Locations
- 🇺🇸
Pharmacosmos Investigational Site, Fairfax, Virginia, United States
🇺🇸Pharmacosmos Investigational Site1, San Antonio, Texas, United States
🇺🇸Pharmacosmos Investigational Site2, San Antonio, Texas, United States
IV Iron Treatment of Restless Legs Syndrome
Phase 2
Withdrawn
- Conditions
- Restless Legs Syndrome
- Interventions
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2015-06-30
- Lead Sponsor
- Pharmacosmos A/S
- Registration Number
- NCT02484768
A Non-interventional Study of Diafer in Subjects With CKD on Haemodialysis for Treatment of Iron Deficiency
Completed
- Conditions
- Anaemia in Chronic Kidney Disease
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 209
- Registration Number
- NCT02301026
- Locations
- 🇬🇧
Morriston Hospital, Renal Department, Swansea, Wales, United Kingdom
🇸🇪Heleneholmsdialysen, Malmö, Sweden
A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo
Phase 3
Withdrawn
- Conditions
- Iron Deficiency Anemia
- Interventions
- Drug: Natrium Chloride 0,9%
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Pharmacosmos A/S
- Registration Number
- NCT02172001
IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose
Phase 3
Completed
- Conditions
- Iron Deficiency Anaemia
- Interventions
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 511
- Registration Number
- NCT02130063
Time to Relapse of Iron Deficiency Anemia After Standard Treatment With a New Intravenous Iron (Monofer®)
Completed
- Conditions
- Iron Deficiency Anemia
- Interventions
- Drug: 10% Iron Isomaltoside 1000
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 391
- Registration Number
- NCT01900197
Treatment of Women After Severe Postpartum Haemorrhage
Phase 3
Completed
- Conditions
- Severe Postpartum Haemorrhage
- Interventions
- Drug: Red blood cell transfusion
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 13
- Registration Number
- NCT01895205
Treatment of Women After Postpartum Haemorrhage
Phase 3
Completed
- Conditions
- Postpartum Haemorrhage
- Interventions
- Other: Standard medical Care
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 200
- Registration Number
- NCT01895218
A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-deficient Blood Donors
Phase 3
Completed
- Conditions
- Iron-deficiency
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2018-03-15
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 107
- Registration Number
- NCT01895231
© Copyright 2025. All Rights Reserved by MedPath